Harry Rowland
Harry Rowland

CEO: Harry Rowland
Based: Lisle, Illinois
Founded: 2007
Company website

The scoop

Endotronix aims to transform the treatment of heart failure, a chronic, progressive condition in which the heart is unable to pump enough blood to support the body. The company is working on a pair of solutions that will provide patients, clinicians and caregivers with a data-driven approach to managing heart failure outside the hospital setting.

These are a cloud-based patient disease management system and an implant that measures blood pressure in the pulmonary artery (PA). Endotronix's bet is that real-time monitoring, along with better communication between doctors and their patients, will lead to more efficient heart failure management and care that could potentially keep heart failure events at bay.

What makes Endotronix fierce

Heart failure management is typically multifaceted—it can involve lifestyle changes, medications, surgery or the implantation of a medical device, such as an implantable cardioverter-defibrillator.

"Heart failure management is still predominantly driven by hospital and in-office visits," said CEO Harry Rowland, Ph.D. "There haven't been solutions in place to deliver more proactive management outside the hospital—everything is set up around a hospital system."

Endotronix's Cordella Heart Failure System is designed to plug this gap. The cloud-based platform may be used with or without the Cordella PA pressure sensor. After seeing a cardiology care team, a patient will go home with a management program and the myCordella App, for the daily measurement of physiological data, including blood pressure, pulse, weight and heart rate.

"The patient will interface with an app that asks very simple health assessment questions," Rowland said. The process, which takes just a few minutes, allows clinicians to review their patients' status on a daily basis and, if necessary, follow up and adjust their treatment.

Some patients with advanced heart failure may also receive the PA pressure sensor, which is implanted in an outpatient procedure that takes 30 minutes to an hour. These patients will use a hand-held reader to take blood pressure readings from the sensor, in addition to collecting the aforementioned physiological data. Changes in PA pressure data have been proven to provide an early indication of worsening heart failure. The combination will provide physicians with an even more comprehensive view of the patient, Rowland said.

The technology could help the nearly 6 million people in the U.S. who have heart failure by offering the opportunity for earlier intervention. It has the potential to reduce the costs of heart failure to the healthcare system.

What to look for

Endotronix closed a $32 million series C round in July 2016, which was slated for a safety and feasibility study of the PA sensor, as well as the development and commercialization of the patient management system. The former is entering first-in-human studies, while the latter is already in clinical studies, Rowland said.

As for the year ahead, Endotronix aims to complete its safety and feasibility trial and to commercially launch the patient management system. The company aims to start an investigational device exemption study of the Cordella Pulmonary Artery Sensor system within the next 12 months, Rowland said.